Evidence mapPaperPMID 41864748Full record

Trial reportLancet (London, England)2026

Prevention of urinary stones with hydration: a randomised clinical trial of an adherence intervention.

Alana C Desai, Naim M Maalouf, Jonathan D Harper, Sri Sivalingam, John C Lieske, H Henry Lai, Peter P Reese, Hunter Wessells, Hongqiu Yang, Hussein R Al-Khalidi and 4 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in Lancet (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03244189 (Prevention of Urinary Stones With Hydration), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03244189 nacompletednot on this map

Prevention of Urinary Stones With Hydration

TypeinterventionalSponsorDuke UniversityRan2017 to 2024Enrolled1,658ConditionsUrinary StonesArmsFluid prescription, Financial incentive, Structured Problem Solving
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Round up.Indian journal of urology : IJU : journal of the Urological Society of India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alana C DesaiDepartment of Surgery, Division of Urology, Washington University in St Louis, St Louis, MO, USA.
Naim M MaaloufDepartment of Internal Medicine and Charles & Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jonathan D HarperDepartment of Urology, University of Washington School of Medicine, Seattle, WA, USA.
Sri SivalingamGlickman Urological & Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
John C LieskeDepartment of Nephrology and Hypertension, Mayo Clinic Foundation, Rochester, MN, USA.
H Henry LaiDepartment of Surgery, Division of Urology, Washington University in St Louis, St Louis, MO, USA; Department of Anesthesiology, Washington University in St Louis, St Louis, MO, USA.
Peter P ReeseDivision of Renal Electrolyte and Hypertension, Department of Medicine, Perlman School of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Hunter WessellsDepartment of Urology, University of Washington School of Medicine, Seattle, WA, USA.
Hongqiu YangDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Hussein R Al-KhalidiDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA; Department of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
Ziya KirkaliNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
Gregory E TasianChildren's Hospital of Philadelphia, Philadelphia, PA, USA.
Charles D ScalesDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA; Departments of Urology and Population Health Science, Duke University School of Medicine, Durham, NC, USA. Electronic address: chuck.scales@duke.edu.
Urinary Stone Disease Network Investigators

Funding

Urinary Stone Disease Research Network: Scientific Data Research CenterU24DK110988 · NIDDK · DUKE UNIVERSITY · PI Hussein Al-Khalidi, Charles D Scales · 2023 to 2024
$2.8M
Extension of Urinary Stone Disease Research Network (USDRN) at Washington UniversityU01DK110986 · NIDDK · WASHINGTON UNIVERSITY · PI Hing Hung Henry Lai · 2022 to 2022
$989k
Fluid Therapy and Stent Management in Nephrolithiasis, USDRN extensionU01DK110994 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI NAIM M MAALOUF · 2022 to 2022
$968k
Harnessing Behavior to Decrease Urinary Stone Disease Morbidity Research ProjectU01DK110961 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI PETER PHILIP REESE, Gregory Edward Tasian · 2022 to 2022
$690k
UW USDRN Clinical CenterU01DK110954 · NIDDK · UNIVERSITY OF WASHINGTON · PI Jonathan D. Harper, HUNTER WESSELLS · 2022 to 2022
$612k
NIDDK NIH HHS U01 DK110954NIDDK NIH HHS U01 DK110961NIDDK NIH HHS U01 DK110986NIDDK NIH HHS U01 DK110988NIDDK NIH HHS U01 DK110994NIDDK NIH HHS U24 DK110988
6 · The paper itself

Abstract

backgroundIncreased fluid intake is universally recommended to decrease the risk of recurrent urinary stones; however, adherence is challenging. The effectiveness of interventions to maintain high fluid intake has not been well studied. We sought to determine whether a multicomponent behavioural intervention programme to promote high fluid intake reduces symptomatic stone recurrence, compared with a control.

methodsIn this randomised clinical trial, participants aged 12 years and older with a history of urinary stone disease and low 24 h urine volumes based on current guidelines were enrolled at six academic medical centres in the USA. Participants were randomly assigned in a 1:1 ratio to a multicomponent behavioural intervention designed to promote increased fluid intake or to the control group receiving guideline-concordant care. The intervention consisted of a fluid prescription, financial incentives to adhere to fluid prescription, health coaching to overcome barriers to consuming more fluids, and patient-selected approaches such as text messaging to maintain increased fluid intake. Randomisation assignment was computer-generated remotely, and investigators, treating physicians, outcome assessors, and adjudicators were masked to group assignment. The primary outcome was symptomatic stone recurrence defined as stone passage or procedural intervention for stone(s) during a 2-year follow-up period, analysed in the intention-to-treat population. Secondary outcomes included change in 24 h urine volume, urinary symptoms, radiographic stone recurrence or growth, and a composite outcome of symptomatic stone recurrence, new stone formation, and growth of existing stone(s); hyponatremia requiring hospitalisation was the safety endpoint. This trial is registered with ClinicalTrials.gov, NCT03244189.

findingsBetween Oct 26, 2017, and Feb 18, 2022, 1658 participants were randomly assigned to intervention (n=826) and control (n=832) groups (median age 44 years [IQR 29-59]; 946 [57%] female). At a median follow-up of 738 days (IQR 711-778), symptomatic stone events occurred in 154 (19%) participants in the intervention group and 165 (20%) in the control group (hazard ratio 0·96, 95% CI 0·77-1·20). Among these 1658 participants, 1104 (66·6%) were recurrent stone formers. 24 h urine volume increased from baseline in both groups and was higher in the intervention group at months 6, 12, 18, and 24 compared with the control group. Urinary storage symptoms of frequency, urgency, and nocturia were greater in the intervention group versus control at months 6 and 12 but not at other timepoints. There was no difference in stone growth of at least 2 mm or new stones between groups from baseline to end-of-study imaging, and the composite outcome of symptomatic stone recurrence, new stone formation, or stone growth of at least 2 mm was also not statistically different between groups. No episodes of hyponatremia requiring hospitalisation (safety endpoint) were reported; 12 (1%) participants in the intervention group had asymptomatic hyponatraemia versus two (<1%) participants in the control group.

interpretationA behavioural intervention programme to promote fluid intake for secondary stone prevention did not reduce recurrent stone events but modestly increased urine volume compared with guideline-based care during a 2-year follow-up period.

fundingNational Institute of Diabetes and Digestive and Kidney Diseases.

Indexed as

Adherence InterventionsDrinkingFluid TherapyPatient ComplianceUrinary CalculiAdolescentAdultFemaleHumansMaleMiddle AgedRecurrenceSecondary PreventionTreatment Outcome

Identifiers

PMID41864748
PMCPMC13043023

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.